ArticleESMO open2025
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer.
Article in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipid metabolism reprogramming: key mechanism of breast cancer endocrine therapy resistance.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndocrine therapy with tamoxifen (TAM) or aromatase inhibitors (AI) is an effective treatment of patients with estrogen receptor-positive, HER2-negative luminal breast cancer. However, many patients do not respond to this therapy, leading to disease recurrence. This study aimed to identify baseline clinical, molecular, and genetic features associated with menopause status, primary endocrine therapy resistance and long-term outcomes in luminal breast cancer. PATIENTS AND
methodsWe analyzed 220 patients from the WSG-ADAPT trial with early-stage, estrogen receptor-positive, HER2-negative breast cancer, who received 3 weeks of preoperative endocrine therapy with TAM or AI. Tumor samples obtained before treatment were profiled using the NanoString BC360 panel, and samples obtained after treatment were analyzed for recurrent genomic alterations by next-generation panel sequencing. A subset of the TCGA-BRCA cohort was used for external validation. Univariate Cox regression analyses were used for prognosis analysis.
resultsThe NanoString signatures were clustered into three stable blocks: A (reactive microenvironment and stemness), B (immune) and C (proliferation and genomic risk). Non-responders more frequently harbored TP53 mutations, which were linked to significantly elevated protumorigenic immune- (interferon-γ, inflammatory chemokines, macrophages and regulatory T cells) and proliferation-related [breast cancer proliferation, genomic risk, and homologous recombination deficiency (HRD)] signature scores. In the AI group, signatures associated with reduced disease-free survival included breast cancer p53 [hazard ratio (HR) 2.74, 95% confidence interval (CI) 1.08-6.94]; genomic risk (HR 2.5, 95% CI 1.07-5.83); HRD (HR 2.44, 95% CI 1.12-5.29) and hypoxia (HR 2.12, 95% CI 1.17-3.87). High expression of programmed cell death protein 1 (HR 0.44, 95% CI 0.21-0.94) and progesterone receptor (HR 0.24, 95% CI 0.07-0.81) indicated better outcomes, respectively. These associations were validated using external data.
conclusionsEndocrine resistance in luminal breast cancer is characterized by elevated immune signatures, increased proliferation, and specific genomic alterations. The integration of clinical information, gene expression patterns, and genetic data enhances patient stratification and potentially informs treatment decisions. These findings support the use of integrative analyses to guide personalized endocrine therapy and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.